Alessandro Mancini

Dr. Alessandro Mancini

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
RSRaffaele Simeoli
Raffaele Simeoli
SCSara Cairoli
Sara Cairoli
FGFederica Galaverna
Federica Galaverna
MBMarco Becilli
Marco Becilli
EBEmilia Boccieri
Emilia Boccieri
BGBianca Maria Goffredo
Bianca Maria Goffredo

16 May 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RSRaffaele Simeoli
Raffaele Simeoli
SCSara Cairoli
Sara Cairoli
MGMarcella Greco
Marcella Greco
FBFrancesco Bellomo
Francesco Bellomo
AMAlessandro Mancini
Alessandro Mancini
BGBianca Maria Goffredo
Bianca Maria Goffredo
Cystinosis is a rare lysosomal storage disorder caused by autosomal recessive mutations in the CTNS gene that encodes for the cystine transporter cystinosin, which is expressed on the lysosomal membrane mediating the efflux of cystine. Cysteamine bitartrate is a cystine-depleting aminothiol agent approved for the treatment of cystinosis in children and adults. In this study, we developed and validated a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for the determination of cysteamine levels in plasma samples. This LC-MS/MS method was validated according to the European Medicines Agency (EMA)’s guidelines for bioanalytical method validation. An ultra-performance liquid chromatograph (UPLC) coupled with a 6470 mass spectrometry system was used for cysteamine determination. Our validated method was applied to plasma samples from n = 8 cystinosis patients (median, interquartile range (IQR) = 20.5, 8.5–26.0 years). The samples were collected before cysteamine oral administration (pre-dose) and 1 h after (post-dose). Our bioanalytical method fulfilled the regulatory guidelines for method validation. The cysteamine plasma levels in pre-dose samples were 2.57 and 1.50–3.31 μM (median and IQR, respectively), whereas the post-dose samples reported a cysteamine median concentration of 28.00 μM (IQR: 17.60–36.61). Our method allows the rapid determination of cysteamine plasma levels. This method was successfully used in cystinosis patients and, therefore, could be a useful tool for the evaluation of therapy adherence and for future pharmacokinetic (PK) studies involving a higher number of subjects.

10 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AMAlessandro Mancini
Alessandro Mancini
RSRaffaele Simeoli
Raffaele Simeoli
LCLuca Cristiani
Luca Cristiani
SCSara Cairoli
Sara Cairoli
Fabiana CicirielloFabiana Ciciriello
Fabiana Ciciriello
BGBianca Maria Goffredo
Bianca Maria Goffredo
Background: “CFTR modulators” (also named “caftor”) have been developed and introduced into clinical practice to improve the functionality of defective CFTR protein. Therapeutic drug monitoring (TDM) is not currently used for CFTR modulators in routine clinical practice and there is still much to learn about the pharmacokinetic/pharmacodynamic (PK/PD) and the safety profiles of these drugs in a real-world setting. Moreover, therapeutic ranges are not yet available for both pediatric and adult cystic fibrosis (CF) patients. Methods: A new and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method for contemporary quantification of ivacaftor (IVA), tezacaftor (TEZ) and elexacaftor (ELX) in plasma samples has been developed and validated. The clinical performance of our method has been tested on samples collected during the routine clinical practice from n = 25 pediatric patients (aged between 7 and 17 years) affected by cystic fibrosis. This LC-MS/MS method has been validated according to ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines for the validation of bioanalytical methods. Results: Our method fulfilled ICH guidelines in terms of accuracy, precision, selectivity, specificity and carry-over. Intra- and inter-day accuracy and precision were ≤15%. The 9-day autosampler stability was 90–100% for TEZ and ELX; meanwhile, it fell to 76% for IVA. An injection volume of 1 µL and a wider quantification range (0.1–20 µg/mL) represent a novelty of our method in terms of sensitivity and fields of application. Finally, the evaluation of PK exposure parameters for IVA revealed strong agreement with previously published reports and with results from the summary of product characteristics (SmPCs). Conclusions: This method could be adopted to contemporarily measure ELX/TEZ/IVA plasma levels for both PK studies and monitor therapy compliance, especially in case of poor or partial responses to treatment, or to evaluate drug–drug interactions when multiple concomitant medications are required. Considering also the high cost burden of these medications to the health system, a TDM-based approach could facilitate more cost-effective patient management.

26 March 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CRChiara Rossi
Chiara Rossi
RSRaffaele Simeoli
Raffaele Simeoli
GAGiulia Angelino
Giulia Angelino
SCSara Cairoli
Sara Cairoli
FBFiammetta Bracci
Fiammetta Bracci
BGBianca Maria Goffredo
Bianca Maria Goffredo
Background: Therapeutic drug monitoring (TDM) of infliximab (IFX) and adalimumab (ADL) mainly relies on the use of enzyme-linked immunosorbent assays (ELISA). More recently, rapid assays have been developed and validated to reduce turnaround time (TAT). Here, we compared IFX and ADL concentrations measured with both ELISA and a new fluorescence-based lateral flow immunoassay (AFIAS). Methods: In serum samples from pediatric patients, IFX and ADL drug levels, and total anti-IFX antibodies were measured using clinically validated ELISA kits (Immundiagnostik AG). Samples were further analyzed using a new rapid assay (AFIAS, Boditech Med Inc.) to measure drug levels and total anti-IFX antibodies. Results: Spearman’s correlation coefficients (rho) were 0.98 [95% confidence interval (CI) 0.97 to 0.99] for IFX (p < 0.001) and 0.83 (95% CI 0.72 to 0.90) for ADL (p < 0.001). Calculated % bias was −14.09 (95% Limits of agreement, LoA, −52.83 to 24.66) for IFX and 15.79 (LoA −37.14 to 68.73) for ADL. For the evaluation of total anti-IFX antibodies, we did not collect sufficient data to establish a statistically significant correlation between AFIAS and ELISA. The inter-rater agreement showed a “substantial” and a “moderate” agreement for IFX and ADL, respectively. Conclusions: Our results show that the AFIAS assay has an accuracy and analytical performance comparable to that of the ELISA method used for TDM of IFX and ADL. Therefore, the introduction of this device into routine clinical practice could provide results more quickly and with similar accuracy as ELISA, allowing clinicians to rapidly formulate clinical decisions.

1 April 2016 in Clinical Neurophysiology
Verified
Journal Article
Closed access
GSGiuseppe Stipa
Giuseppe Stipa
SCStefano Caproni
Stefano Caproni
EME. Moschini
E. Moschini
ASA. Sensidoni
A. Sensidoni
DFD. Frondizi
D. Frondizi
SCS. Carletti
S. Carletti

1 December 2017 in Clinical Neurophysiology
Verified
Journal Article
Closed access
GSGiuseppe Stipa
Giuseppe Stipa
SCS. Carletti
S. Carletti
DFD. Frondizi
D. Frondizi
CFC. Fanelli
C. Fanelli
DGD. Gobbi
D. Gobbi
Carlo ColosimoCarlo Colosimo
Carlo Colosimo